Senseonics Holdings, Inc. (SENS)
Market Cap | 573.91M |
Revenue (ttm) | 14.83M |
Net Income (ttm) | 214.99M |
Shares Out | 478.26M |
EPS (ttm) | 0.02 |
PE Ratio | 60.00 |
Forward PE | 21.51 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,755,544 |
Open | 1.21 |
Previous Close | 1.25 |
Day's Range | 1.19 - 1.27 |
52-Week Range | 0.77 - 3.89 |
Beta | 0.88 |
Analysts | Sell |
Price Target | 2.07 (+72.5%) |
Earnings Date | Feb 27, 2023 |
About SENS
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serve... [Read more]
Financial Performance
In 2021, SENS's revenue was $13.68 million, an increase of 176.32% compared to the previous year's $4.95 million. Losses were -$302.47 million, 72.7% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SENS stock is "Sell." The 12-month stock price forecast is $2.07, which is an increase of 72.50% from the latest price.
News

Senseonics Announces Equity Grants To Employees Under Inducement Plan
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous gluc...

Senseonics to Present at the Stifel 2022 Healthcare Conference
GERMANTOWN, Md.

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results
GERMANTOWN, Md.

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense® E3 CGM GERMANTOWN, Md. , Nov. 3, 2022 /PRNewswire/ -- Senseonics Hol...

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time
GERMANTOWN, Md.

Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Senseonics Announces CFO Transition
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose...

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 12.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Why Is Senseonics (SENS) Stock Heating Up Today?
Senseonics (NYSEAMERICAN: SENS) stock jumped by over 50% after it announced its Eversense implantable glucose monitor was approved for coverage by Elevance Health (NYSE: ELV), formerly known as Anth...

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose...

Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose...

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose...

7 Undervalued Penny Stocks to Buy for Massive Gains
These seven undervalued penny stocks each have the potential to pay off for investors down later down the road. The post 7 Undervalued Penny Stocks to Buy for Massive Gains appeared first on InvestorP...

Senseonics to Participate in the Jefferies Healthcare Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Senseonics to Participate in the H.C. Wainwright Global Investment Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
3 Zombie Companies That Still Have Hope for New Life
The unprecedented expansionary fiscal and monetary policies during the pandemic may have caused a significant surge in zombie companies. The post 3 Zombie Companies That Still Have Hope for New Life a...

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous gl...

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...

Senseonics Announces Equity Grants to Employees Under Inducement Plan
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous ...

Senseonics Holdings (SENS) Beats Q4 Earnings and Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 133.33% and 0.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?